Pharmafile Logo
Pharmafocus logo
Advanced Search

Astellas Pharma

Showing 15 posts of 18 posts found.

Astellas and Kelonia Therapeutics enter agreement for development of immuno-oncology therapeutics

February 16, 2024
Research and Development Astellas Pharma, Kelonia Therapeutics, Oncology, collaboration, immuno-oncology

Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of Astellas) and Kelonia have entered …

News

Astellas Pharma to acquire Propella Therapeutics for $175m

November 20, 2023
Business Services Astellas Pharma, Oncology, Properlla Therapeutics, acquisition

Astellas Pharma and Propella Therapeutics have announced that Astellas and Propella have entered a merger agreement in which Astellas will …

News

Astellas plans to invest over €330m in new facility in Ireland

September 18, 2023
Manufacturing and Production Astellas Pharma, Ireland, Pharmacy, facility, manufacturing

Astellas Pharma has announced that it is preparing to submit a planning application to build a new state-of-the-art facility at …

News

Astellas set to open new life sciences facilities in Cambridge, Massachusetts

August 10, 2023
Business Development Astellas Pharma, Pharmacy, pharmaceutical, science facility

On 9 August 2023, Astellas Pharma announced its plans to open what it has described as a “state-of-the-art life sciences …

News
eye2

Astellas announces FDA approval for Izervay for GA treatment

August 7, 2023
Medical Communications AMD, Astellas Pharma, FDA, Izervay, Opthalmology, geographic atrophy

Astellas Pharma has announced that the US Food and Drug Administration (FDA) has approved Izervay (avacincaptag pegol intravitreal solution) for …

News
eye2

Astellas and 4D Molecular Therapeutics enter license agreement for rare ophthalmic targets

July 11, 2023
Research and Development 4D Molecular Therapeutics, AAV vectors, Astellas Pharma, Opthalmology, ophthalmology

Astellas Pharma and 4D Molecular Therapeutics (4DMT) have announced a license agreement under which Astellas has the right to use …

News

FDA grants Priority Review for Astellas Pharma’s BLA for cancer drug

July 6, 2023
Research and Development Astellas Pharma, Biologics License Application, FDA, GEJ, Oncology

Japanese pharmaceutical company Astellas Pharma has announced that the US Food and Drug Administration (FDA) has granted Priority Review for …

News

Astellas establishes open innovation hub for tumour microenvironment research

June 29, 2023
Research and Development Astellas Pharma, Mitsui Fudosan, Oncology, open innovation hub, tumour microenvironment

Astellas Pharma and Mitsui Fudosan have announced that Astellas plans to establish a tumour microenvironment (TME) open innovation hub, intended …

News

Astellas Pharma shares positive results from phase 3b trial of Fezolinetant for menopause symptoms

June 28, 2023
Medical Communications Astellas Pharma, Pharmacy, clinical trial, fezolinetant, menopause

Astellas Pharma has announced positive topline results from the phase 3b DAYLIGHT clinical trial for fezolinetant, its investigational oral, nonhormonal …

News
acute_lymphoblastic_leukaemia_smear

Astellas Pharma and BMT CTN announce phase 3 data for gilteritinib

June 9, 2023
Research and Development Astellas Pharma, BMT CTN, Haematology, gilteritinib, leukaemia, pharmaceutical

Japanese pharmaceutical company Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) have presented their phase …

News

Astellas and Sony enter collaborative research agreement

May 16, 2023
Research and Development ADC, Astellas Pharma, Oncology, Sony, research agreement

Sony and Astellas Pharma have announced that they have entered into a collaborative research agreement in an attempt to discover …

News

FDA approve Astellas’s Myrbetriq treatment for bladder dysfunction

March 26, 2021
Medical Communications Astellas Pharma, FDA, Ida approval

The FDA have approved a new indication for Astellas Pharma’s Myrbetriq and Myrbetriq Granules to treat neurogenic detrusor overactivity (NDO), …

News
astellas_tokyo_copy_9

FDA approves Seattle Genetics and Astellas Pharma’s bladder cancer drug

December 19, 2019
Business Services Astellas Pharma, Cancer, Padcev, Seattle Genetics, bladder cancer

The FDA has granted accelerated approval for Seattle Genetics and Astellas Pharma’s bladder cancer drug Padcev (enfortumab vedotin-ejfv). The drug’s …

News

FDA approves Pfizer and Astellas Pharma’s prostate cancer drug

December 17, 2019
Manufacturing and Production Astellas Pharma, Cancer, FDA, Pfizer, Xtandi, prostate cancer

The FDA has approved Pfizer and Astellas Pharma’s Xtandi (enzalutamide) to treat patients with a type of prostate cancer. The …

News
266812

Jamie McGarvey joins Astellas Pharma communications team

September 18, 2015
Medical Communications Astellas, Astellas Pharma, Jamie McGarvey

Astellas Pharma has appointed Jamie McGarvey as senior manager of employee communications within its corporate affairs department.  McGarvey will be …

Appointment

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024